Abstract: The present invention relates to a protection-effective amount of UV-damaged RNA fragments, in combination with a cosmetically or pharmaceutically acceptable carrier. The compositions are useful in the prevention of skin damage to UV radiation and in preventing photoaging.

Abstract: A method is disclosed for coating a biomaterial to be placed in contact with a patient's blood flow to inhibit blood coagulation from adhering to the biomaterial that would otherwise result from such contact. A biodegradable material of liquid state compatible with the blood and tissue of the human body is prepared, and an anti-coagulant drug is incorporated into the liquid state of the biodegradable material to form a liquid coating material. The liquid coating material is adhesively applied to a surface of the biomaterial in a substantially continuous overlying layer having a formulation, pattern and thickness selected according to the period of time over which the coating material is to perform its anti-coagulant action. Thereafter the coating material is dried to a layer thickness less than about 100 microns for continuous disintegration thereof as a function of time when the layer is in contact with flowing blood.

Abstract: A medical polymer gel produced by immobilizing a drug onto a water swelling polymer gel through a cleavable group with the main chain to be cleaved via an enzymatic reaction and a spacer, and a water swelling polymer gel produced by covalently crosslinking a polysaccharide having a carboxyl group within the molecule with a diaminoalkane derivative as the crosslinking reagent. Because the medical polymer gel exerts a drug releasing property depending on the level of an enzyme, the gel can release a therapeutically effective dose of a drug only at a focal lesion generating the enzyme. The medical polymer gel is useful as the structural component of wound dressings, adhesives for biological tissues, adhesion preventing agents, bone reinforcing agents, and drug releasing base materials. Wound dressings comprising the structural material of the water swelling polymer gel of the present invention, can be applied to a patient with wound, burn, and decubitus to promote the healing of the wounds of the patient.

Abstract: The present invention relates to a ready-to-use indomethacin eye lotion comprising, in aqueous solution:indomethacin,a .beta.- or .gamma.-cyclodextrin etherified with C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 hydroxyalkyl groups, the cyclodextrin being present in a molar ratio with respect to the indomethacin of at least 10/1, and the pH of the solution being from 4.0 to 6.0.

Abstract: Wart of human being is prevented or cured by administration of a pharmaceutical composition containing an eight structural polymer of 2-oxygermylpropionic acid having an empirical formula of C.sub.6 H.sub.10 Ge.sub.2 O.sub.7, a minimum constitutional unit of (O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH and the following stereostructure: ##STR1## wherein R stands for --CH.sub.2 CH.sub.2 COOH and m is an integer of 137.+-.84.

Abstract: A low-sensitizing medicament for use in treating skin-tear injuries includes an emulsified water and hydrocarbon carrier portion, an emollient portion, a hydroxyquinoline antimicrobial portion, a mild keratolytic portion, and a paraben preservative portion. Additional ingredients include a zinc oxide topical protectant, vitamin E, a buffer or alkalizer agent that adjusts pH in a range from 6.5 to 6.8, and a scenting agent.

Abstract: Method for extracting malodorous compounds present in a liquid formulation containing at least one compound bearing a thiol functional group of formula:HS--A--Y--B (I)in which said formulation is placed in contact with a pulverulent absorbing agent, in order to obtain a deodorized composition, intended for a subsequent use, said absorbing agent being such that, when it is suspended in an aqueous solution containing 92 g/l of thioglycolic acid, said aqueous solution also contains at least 30% by weight of the initial thioglycolic acid after contact for 15 minutes.

Abstract: A method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering astaxanthin in a therapeutically-effective amount to prevent, retard or treat eye and central nervous system diseases or injuries, such as age-related macular degeneration and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases.

Abstract: Mannose-6- and 1-phosphates and their pharmaceutically acceptable salts and bioprecursors thereof are useful in the treatment of fibrotic disorders. They accelerate wound healing and the 6-phosphate prevents or mitigates scar formation. The invention includes particular, appropriate formulations of the mannose phosphate.

Abstract: Compositions useful to at least partially correct an effect of ametropia in a mammalian eye are disclosed. Such compositions comprise a plurality of particles sized and adapted to be placed in proximity to the outer surface of the cornea of a mammalian eye to at least partially correct an effect of ametropia in the mammalian eye. Each of the plurality of particles carries a complete hologram, preferably a complete hologram which holds all the information needed to at least partially correct the effect of ametropia in the mammalian eye. A particularly useful method of administering the plurality of particles to a mammalian eye is to use an additional component in an amount effective to act as a carrier for the plurality of particles. In one embodiment, this carrier component is an ophthalmically acceptable, aqueous-based liquid. Methods for using such compositions to at least partially correct an effect of ametropia in the mammalian eye, and methods for producing such compositions are also disclosed.

Abstract: Saline solutions useful in treating contact lenses are described. Unlike prior saline solutions used for similar purposes, the present solutions do not contain conventional antimicrobial agents which are potentially toxic to ocular tissues. Rather, the solutions contain a combination of a borate-polyol complex, one or more anionic or nonionic surfactants, and a low molecular weight amino acid (e.g., glycine). It has been found that this combination effectively preserves the saline solutions from antimicrobial contamination, is relatively nontoxic to ocular tissues, and is compatible with oxidizing agents used in certain contact lens disinfecting systems. The combination also facilitates the cleaning of contact lenses.

Abstract: A composite particle timed release pest control agent comprising a dense core particle, a floatation particle, a pesticide, and a composite forming adhesive. The density of the core particle adapts the composite for broadcast application to aqueous and periodically flooded treatment locus and causes the composite to penetrate foliage to contact environmental water. After contact with water at a treatment locus, water causes the adhesive to soften disassembling the composite particle releasing the floatation particle and the pesticide to the surface of the environmental water. At the surface the dissolution rate of the adhesive causes a timed release of the pesticide for action. The composite particle of the invention can be formulated in a quick release formulation that releases the active pest control agent for control in a one to twelve day period or within 0.1 to 72 hours. A long lasting slow release composite can be manufactured that can be used to obtain effective pest control for 10 to 30 days.

Abstract: Provided is a medical compound and a surgical tape containing the medical compound for curing muscle ache and stiffness. The medical compound is capable of radiating farinfrared in the wavelength rang of 3-16 .mu.m when stimulated by body heat. It has the effects of vitalizing cells and promoting metabolism. The medical compound is composed of powdered perelite and at least one metallic oxide such as Ta.sub.2 O.sub.5, Nb.sub.2 O.sub.5, NiO and the like, which will not cause environmental pollution when the surgical tape is discarded after use.

Abstract: A solid preparation soluble in the buccal cavity, which is composed of a sugar comprising lactose and/or mannitol and 0.1-1.2 w/w%, based on the sugar, of agar and an active ingredient and has a density of 400 to 1,000 mg/ml and such a strength as to withstand the handling in the manufacture thereof. It has such a sufficient practical solubility in the buccal cavity that even the aged or children having difficulty in swallowing a solid preparation, such as a tablet, can take it. It has an exceedingly high strength as compared with conventional open matrix structures and hence can withstand satisfactorily carrying and PTP packaging.

Abstract: A device for pinpoint application of micro-quantities of a pharmacologically suitable composition to the outer hard coat of the eye, comprises a micro-container with a fixation element. The micro-container comprises a bore whose aperture is adapted to contact the eye surface, and the fixation element is adapted for reversibly adhering to the eye surface.

Abstract: A hot pepper paper system comprising a sheet of paper in a rectangular configuration having long front and rear edges and having short side edges therebetween. The sheet of paper has a front side and a back side. Further included is a layer of an insect repelling material on the front side of the paper.

Abstract: An improved biocompatible composition consisting of physiologically stable microparticles carried in a lubricative suspension, solution, other fluid or gel is presented. The composition is intended to be delivered into the body through a small-bore needle, cannula, or catheter and to a tissue site for the purpose of augmenting the tissue site and surrounding area, thereby correcting a defect, filling a void, or strengthening the support structures of the tissue. The particles are a hard, metallic substance and are carbon-coated.

Abstract: There is provided an orally administrable cholesterol lowering agent which is obtained by coating with hydroxypropylmethylcellulose plain tablets containing an anion exchange resin as an active component and containing 14-20% by weight of water and not more than 2% by weight of silicon dioxide based on the weight of the anion exchange resin. The orally administrable cholesterol lowering agent is obtained by coating the above mentioned tablets with an aqueous solution of 10-30 cSt of hydroxypropylmethylcellulose. In addition to being characterized by easiness of swallowing, the orally administrable cholesterol lowering agent of the present invention is superior in compressing shapability, stability in a moistening environment, and fluidity.

Abstract: A topical cosmetic composition contains a cosmetic carrier and a mixture of fatty acid triglycerides. The fatty acids of the triglycerides include 40% to 70% by weight oleic acid, 30% to 50% by weight polyunsaturated acids, 0.2% to 1.0% by weight gamma-linolenic, 1% to 5% by weight alpha-linolenic acid, and the ratio by weight of n-6 fatty acids to n-3 fatty acids with a degree of unsaturation of 3 or more in the triglycerides is 10:1 to 30:1.

Abstract: A pharmaceutical dosage unit defined by a sheath composed of a bioadhesive material which surrounds one or more capsules and one or more nonliquid supports containing the active pharmaceutical ingredient. The capsules are made of a mixture of approximately 70% gelatin and 30% glycerin. The supports can be tablets. The dosage unit is useful in providing a sustained release effect of the pharmaceutical ingredient in the lower part of the rectum for a period of 24 hours.